Markowiak, Till and Ansari, Mohammed Khalid Afeen and Neu, Reiner and Schalke, Berthold and Marx, Alexander and Hofmann, Hans-Stefan and Ried, Michael (2021) Evaluation of Surgical Therapy in Advanced Thymic Tumors. CANCERS, 13 (18): 4516. ISSN , 2072-6694
Full text not available from this repository. (Request a copy)Abstract
Simple Summary A complete resection of thymic tumors is known to be the most important prognostic factor, but it is often difficult to perform, especially in advanced stages. In this study, patients with advanced thymic tumors who underwent radical resection were examined retrospectively. The primary endpoint was defined as the postoperative resection status. Secondary endpoints included postoperative morbidity, mortality, and survival. In tumor stages III a microscopic complete resection was achieved in 53.3% of patients. In stages IV a macroscopic complete resection was documented in 76.7% of patients. Surgical revision was necessary in 17.8% of patients. In-hospital mortality was 2.7%. The 5-year survival rate of all patients was 61.3%. In particular, median survival after macroscopic incomplete resection was significantly short. Advanced thymic tumors can be resected with an acceptable risk of complications and low mortality. In stage III as well as in stage IV the promising survival rates are dependent on the resection-status. A complete resection of thymic tumors is known to be the most important prognostic factor, but it is often difficult to perform, especially in advanced stages. In this study, 73 patients with advanced thymic tumors of UICC stages III and IV who underwent radical resection were examined retrospectively. The primary endpoint was defined as the postoperative resection status. Secondary endpoints included postoperative morbidity, mortality, recurrence/progression-free, and overall survival. In total, 31.5% of patients were assigned to stage IIIa, 9.6% to stage IIIb, 47.9% to stage IVa, and 11% to stage IVb. In stages III a R0 resection was achieved in 53.3% of patients. In stages IV a R0/R1 resection was documented in 76.7% of patients. Surgical revision was necessary in 17.8% of patients. In-hospital mortality was 2.7%. Median recurrence/progression-free interval was 43 months (p = 0.19) with an overall survival of 79 months. The 5-year survival rate was 61.3%, respectively. Median survival after R2 resection was 25 months, significantly shorter than after R0 or R1 resection (115 months; p = 0.004). Advanced thymic tumors can be resected with an acceptable risk of complications and low mortality. In stage III as well as in stage IV the promising survival rates are dependent on the resection-status.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | FORTHCOMING 8TH EDITION; EPITHELIAL TUMORS; TNM CLASSIFICATION; PROGNOSTIC-FACTORS; STAGING PROJECT; THYMOMA; RESECTION; MALIGNANCIES; MANAGEMENT; DIAGNOSIS; thymic tumor; thymoma; thymic carcinoma; hyperthermic intrathoracic chemotherapy |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Thoraxchirurgie Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 02 Aug 2022 10:03 |
| Last Modified: | 02 Aug 2022 10:03 |
| URI: | https://pred.uni-regensburg.de/id/eprint/46002 |
Actions (login required)
 |
View Item |
